Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey

Angela M. Thompson-Paul, PhD, MSPH, Stanley C. Wei, MD, MPH, Christine L. Mattson, PhD, McKaylee Robertson, MPH, Alfonso C. Hernandez-Romieu, MD, MPH, Tanvir K. Bell, MD, and Jacek Skarbinski, MD

**Abstract:** Our objective was to compare obesity prevalence among human immunodeficiency virus (HIV)-infected adults receiving care and the U.S. general population and identify obesity correlates among HIV-infected men and women.

Cross-sectional data was collected in 2009 to 2010 from 2 nationally representative surveys: Medical Monitoring Project (MMP) and National Health and Nutrition Examination Survey (NHANES).

Weighted prevalence estimates of obesity, defined as body mass index $\geq 30.0 \text{kg/m}^2$, were compared using prevalence ratios (PR, 95% confidence interval [CI]). Correlates of obesity in HIV-infected adults were examined using multivariable logistic regression.

Demographic characteristics of the 4006 HIV-infected adults in MMP differed from the 5675 adults from the general U.S. population in NHANES, including more men (73.2% in MMP versus 49.4% in NHANES, respectively), black or African Americans (41.5% versus 11.6%), persons with annual incomes <$20,000 (64.5% versus 21.9%), and homosexuals or bisexuals (50.9% versus 3.9%). HIV-infected men were less likely to be obese (PR 0.5, CI 0.5–0.6) and HIV-infected women were more likely to be obese (PR 1.2, CI 1.1–1.3) compared with men and women in the general population, respectively. Among HIV-infected women, younger age was associated with obesity (<40 versus >60 years). Among HIV-infected men, correlates of obesity included black or African American race/ethnicity, annual income >$20,000 and <$50,000, heterosexual orientation, and geometric mean CD4+ T-lymphocyte cell count >200 cells/μL.

Obesity is common, affecting 2 in 5 HIV-infected women and 1 in 5 HIV-infected men. Correlates of obesity differ for HIV-infected men and women; therefore, different strategies may be needed for the prevention and treatment.

(Int: 10.1097/MD.0000000000001081)

**Abbreviations:** ART = antiretroviral therapy, BMI = body mass index, CD4 = CD4+ T-lymphocyte cell, CDC = Centers for Disease Control and Prevention, CI = confidence interval, CVD = cardiovascular disease, HIV = human immunodeficiency virus, MMP = Medical Monitoring Project, NHANES = National Health and Nutrition Examination Survey, PR = prevalence ratio, SE = standard error, SPR = standardized prevalence ratio.

**INTRODUCTION**

Since the introduction of combination antiretroviral therapy (ART) in the mid-1990s, human immunodeficiency virus (HIV) associated morbidity and mortality has dramatically declined.\cite{1,2} Life expectancy of HIV-infected adults receiving ART has increased and is approaching that of the general population.\cite{3,4,5} As the population receiving ART ages and lives longer with HIV infection, chronic and age-related conditions are increasingly prevalent and contribute substantially to overall morbidity and mortality.\cite{6,7,8} Less than one-quarter of deaths among HIV-infected persons receiving care are due to AIDS whereas up to half are due to noninfectious causes such as cardiovascular disease (CVD), non-AIDS-related malignancies, and renal disease.\cite{9,10}

Obesity is an independent-risk factor for CVD and obese individuals in the general U.S. population are nearly twice as likely to experience CVD, even after adjustment for other traditional-risk factors.\cite{11} For health care providers and patients, it is important to prevent and treat obesity, as there is an increase in risk for additional comorbid conditions and mortality in persons with body mass index (BMI) $>$30 kg/m\(^2\); for HIV-infected obese persons, this risk may be even greater than in the general population. Several estimates of the prevalence of obesity among HIV-infected adults have been reported in the

**Editor:** Akhilanand Chaurasia.

Received: May 1, 2015; revised: June 3, 2015; accepted: June 4, 2015.

From Division of HIV/AIDS Prevention (AMTP, SCW, CLM, MKR, ACHR, JS); Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia (AMTP); United States Public Health Service, Rockville, Maryland (AMTP, SCW); Oak Ridge Institute for Science and Education (MKR); Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia (ACHR); and Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA (TKB).

Correspondence: Jacek Skarbinski, Division of HIV/AIDS Prevention, CDC/OID/NCHHSTP, 1600 Clifton Road NE, Mail-Stop E-46, Atlanta, GA 30329, USA (e-mail: jskarbinski@cdc.gov).

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.

The CDC provides funds to all states and the District of Columbia, through a Cooperative Agreement (PS09-937), to conduct the HIV surveillance used in this study and to selected areas to conduct the MMP, and provides technical assistance to all funded areas.

AMTP, SCW, MKR, and JS had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept, design, and conduct; and acquisition of data: AMTP, SCW, CLM, and JS. Analysis and interpretation of data: AMTP, SCW, CLM, MKR, ACHR, and JS. Drafting of the manuscript: AMTP, SCW, CLM, and JS. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: AMTP, SCW, ACHR, and JS. Obtained funding: JS. Administrative, technical, and material support: CLM, SCW, and JS. Study supervision: SCW, and JS. The CDC reviewed and approved final submission.

The authors have no conflicts of interest to disclose.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ISSN: 0025-7974

DOI: 10.1097/MD.0000000000001081
literature, ranging from 9% among HIV-infected men in the military\textsuperscript{13} to 33% among HIV-infected women in Alabama\textsuperscript{14} (eTable 1, http://links.lww.com/MD/A327); however, these estimates have been derived from small studies or subpopulations with limited generalizability rather than from large, national, and population-based studies.\textsuperscript{7,11,13–24}

Estimating the prevalence and correlates of obesity is a first step in identifying important comorbid conditions that affect HIV-infected persons and may contribute to increased mortality from non-AIDS-defining conditions.\textsuperscript{6,7} The objectives of this analysis were three-fold: to estimate the prevalence of obesity among HIV-infected individuals receiving medical care at HIV outpatient clinics using nationally representative data; to compare obesity prevalence in HIV-infected individuals receiving medical care at HIV outpatient clinics to that in the general population; and to identify factors associated with obesity in HIV-infected men and women receiving medical care at HIV outpatient clinics.

METHODS

We describe the prevalence of obesity in a nationally representative sample of HIV-infected adults receiving care using population-based data from the 2009 data collection cycle of the Medical Monitoring Project (MMP)\textsuperscript{25–28} and compare it to the prevalence of obesity in a nationally representative sample of the U.S. population from the 2009 to 2010 National Health and Nutrition Examination Survey (NHANES).\textsuperscript{29,30}

Medical Monitoring Project (MMP)

MMP is an HIV surveillance system designed to produce nationally representative estimates of behavioral and clinical characteristics of HIV-infected adults receiving medical care from HIV outpatient facilities in the United States.\textsuperscript{25–28} MMP is funded by the Centers for Disease Control and Prevention (CDC). MMP methods, including weighting procedures, have been described in detail elsewhere.\textsuperscript{25–28} Briefly, MMP has a cross-sectional design in which U.S. states and territories were sampled first, then eligible facilities within each state were selected, and finally, eligible individuals were selected from facilities. Eligible facilities were those that provided outpatient HIV care, defined as the treatment and management of HIV infection, including monitoring CD4\textsuperscript{+} T-lymphocyte cell (CD4) count and HIV viral load tests, or the prescription of ART. For the 2009 data collection cycle, eligible individuals were HIV-infected adults, aged 18 years or older, receiving medical care in participating facilities in 16 states and Puerto Rico, between January and April 2009. Data from MMP were weighted to produce nationally representative estimates of all HIV-infected adults receiving care in the United States. In the 2009 data collection cycle, between June 2009 and May 2010, 100% of sampled states and territories participated, 461 out of 603 sampled facilities participated (facility response rate, 76\%), and 4217 of 9338 sampled persons completed an interview and had their medical records abstracted (patient-level response rate, 51\%). Women who reported having been pregnant in the prior 12 months (n = 47) and persons missing weight data in their medical records (n = 164) were excluded from analysis (Figure 1). We analyzed data on 4006 participants and weighted the data to represent 399,062 HIV-infected adults in HIV medical care in the United States during January to April 2009.

Face-to-face interviews were conducted to collect information on 11 behavioral and clinical domains, characteristics of obesity among HIV-infected adults receiving medical care and adults in the general population of the United States. \textsuperscript{*} Body mass index (BMI) directly calculated as weight in kilograms divided by height in meters squared (kg/m\textsuperscript{2}). \textsuperscript{**} BMI category inferred using available weight data and standard distribution of heights for age and sex in United States.
including gender at birth, race, educational attainment, annual income, sexual orientation, and time since HIV diagnosis were self-reported during interviews. Data on weight, height, stage of disease, prescription of ART, and viral suppression were collected through abstraction of medical records for the year prior to the date of interview.

In accordance with the federal human subjects protection regulations at 45 Code of Federal Regulations 46.101c and 46.102d 13 and with the Guidelines for Defining Public Health Research and Public Health Non-Research, \(^\text{11,12}\) MMP was determined to be a non-research, public health surveillance activity used for disease control program or policy purposes. As such, MMP is not subject to review by a federal institutional review board. CDC officials who were not involved with MMP implementation were required locally.

### National Health and Nutrition Examination Survey (NHANES)

NHANES, conducted by the National Center for Health Statistics, CDC, is a series of cross-sectional nationally representative health examination surveys designed to assess the health and nutritional status of the civilian, noninstitutionalized U.S. population. \(^\text{29,30}\) NHANES relies on a complex, multistage probability sampling design to select a representative sample, selecting counties as the primary sampling unit, then a block or group of blocks within the county, then specific households within each block, and finally individuals within each household. Height and weight were measured in a mobile examination center using standardized techniques and equipment. Participants reported demographic information during the family interview, and sexual orientation was reported by the participant using a computer-assisted personal interviewing system in the mobile examination center. From 10,537 sampled persons, 10,253 persons had both interview and body measurement data; we excluded from analysis persons who were younger than 18 years of age \((n = 4277)\), pregnant \((n = 68)\), or had missing or invalid weight data \((n = 247, \text{Figure 1})\). Of the NHANES participants included in this analysis, 85% reported having a usual place of health care. NHANES 1999 to 2010 underwent National Center for Health Statistics institutional review board/research ethics review board approval; written informed consent was obtained from the participants.

### Analytical Methods

For MMP and NHANES, distribution of sociodemographic characteristics was summarized using unweighted counts and weighted percentages with 95% confidence intervals (CIs). Factors associated with obesity and common to both surveillance systems included gender, age at the time of interview, race/ethnicity, educational attainment, and sexual orientation. \(^\text{14,33–37}\) We additionally examined HIV clinical care factors reported to have variable associations with obesity or weight gain in small studies or subpopulations, including years since HIV diagnosis, CD4 count, HIV disease stage per CDC criteria, \(^\text{38}\) ART prescription, and recent viral suppression (most recent viral load during the past 12 months was undetectable or \(\leq 200 \text{ copies/mL}\)). \(^\text{13,14,16,17,23,39}\)

The weighted prevalence and 95% CI of obesity were estimated separately for men and women, because obesity reports on the general population stratify by gender and because evidence from other studies indicated that the prevalence of obesity among HIV-infected persons may differ by gender. \(^\text{7,13,14,17,18,20}\) BMI was calculated as weight in kilograms divided by height in meters squared \((\text{kg/m}^2)\). Following current recommendations, obesity was defined as a BMI \(\geq 30.0 \text{ kg/m}^2\). When height was missing \((\text{Figure 1})\), BMI category was inferred from recorded weight using the assumption that the heights of respondents fell between the 2.5th and 97.5th percentiles of age and sex-matched members of the U.S. population. \(^\text{40}\) Participants with missing or invalid weight measurements were excluded from analysis \((\text{eTables 2 and 3, http://links.lww.com/MD/A327})\).

For the characteristics common to both surveys, stratum-specific prevalence ratios (PRs) were summarized with standardized prevalence ratios (SPRs, 95% CI), utilizing the weighted prevalence and corresponding standard error (SE). \(^\text{42}\) This approach is an extension of the indirect method for calculating age-adjusted standardized mortality ratios, in which the observed mortality rate in a population of interest is compared with an expected one derived from the age-specific mortality rates of a standard population. \(^\text{43}\)

Among HIV-infected men and women receiving care who participated in MMP, we assessed bivariate associations with Rao–Scott \(X^2\) tests to identify factors associated with obesity. \(^\text{44}\) Variables with \(P \leq 0.15\) in bivariate tests were included in multivariable logistic regression models examining factors independently associated with obesity in HIV-infected men and women. All two-way interactions of significant variables were considered for inclusion; tests for interaction were performed with likelihood ratio tests by comparing 2 nested multivariate models with and without the interaction term, rejecting the null hypothesis with \(P \leq 0.05\). We used predicted marginal probabilities to calculate the adjusted prevalence of obesity in multivariable logistic models. \(^\text{45}\) To assess the effect of missing weight data on our results, we conducted sensitivity analyses to examine differences in sociodemographic characteristics between participants who had complete weight and height data \((\text{BMI directly calculated})\), complete weight data only \((\text{BMI inferred})\), and those who were missing weight data \((\text{excluded from analysis})\). We then removed persons with inferred BMI from the analytic dataset and repeated analyses.

All analyses accounted for complex survey designs, weighted analyses were conducted using SAS-callable SUDAAN (RTI International, Research Triangle Park, NC), PROC SURVEYFREQ and PROC RLOGIST; in SAS 9.3 (SAS Institute, Cary, NC) for MMP and NHANES data. SPR calculations were performed in Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA).

### RESULTS

Among the 4217 MMP participants with matched interview and medical record data during the 2009 data collection cycle, 4006 (95.0%) had sufficient information for calculation or inference of BMI and were included in the analytic sample \((\text{Figure 1})\). From 9075 persons interviewed and examined in NHANES in the 2009 to 2010 cycle, 5661 (62.4%) met inclusion criteria and had sufficient information for calculation of BMI. As shown in Table 1, the MMP population differed from the NHANES population on a number of demographic factors. Compared to NHANES, MMP included a greater proportion of males \((73.2% \text{ versus } 49.4%)\), persons aged 40 to 59 years \((66.0% \text{ versus } 39.4%)\), blacks or African Americans \((41.5% \text{ versus } 11.6%)\), persons with low income \((\text{annual income } <$20,000: 64.5% \text{ versus } 21.9%)\), and homosexual or
bisexual participants (50.9% versus 3.9%). The majority of MMP participants had been diagnosed with HIV for more than 10 years (54.0%), had stage 3 (AIDS, 67.9%), were prescribed ART (83.8%), and had suppressed viral load at their most recent test (72.4%).

Table 2 presents the weighted prevalence (SE), stratum-specific PR, and SPR for obesity in MMP compared with NHANES for men and women. Overall, the prevalence of obesity among HIV-infected adults receiving care, compared to those in the general population was 46% lower in men (PR: 0.54, 95% CI 0.48, 0.61) and 17% higher in women (PR: 1.17, 95% CI: 1.06, 1.30). HIV-infected men receiving care were significantly less likely to be obese compared to men in the general population regardless of age, race/ethnicity, education, income level, or sexual orientation. Among women, SPR for obesity differed by subgroups. HIV-infected women receiving care were more likely to be obese than women in the general US population after standardization for age (SPR: 1.21, 95% CI 0.98, 1.49).
| Characteristic          | MMP Proportion Obese, Weighted % (95% CI) | NHANES Proportion Obese, Weight% (SE) | PR  | SPR (95% CI) |
|-------------------------|------------------------------------------|--------------------------------------|-----|-------------|
| Overall                 | 18.8 (0.7)                               | 34.7 (1.8)                           | 0.54| 0.54 (0.48, 0.61) |
| Age at interview        |                                          |                                      |     |             |
| 18–39 years             | 19.0 (1.3)                               | 30.9 (2.5)                           | 0.62| 0.53 (0.47, 0.59) |
| 40–59 years             | 18.9 (0.9)                               | 37.0 (1.8)                           | 0.51|             |
| ≥60 years               | 17.4 (2.6)                               | 38.1 (2.6)                           | 0.45|             |
| Race/ethnicity          |                                          |                                      |     |             |
| Black or African American | 21.3 (1.2)                              | 37.6 (2.5)                           | 0.57|             |
| White or Caucasian      | 18.4 (1.4)                               | 35.6 (2.2)                           | 0.52|             |
| Hispanic or Latino/a    | 16.8 (1.5)                               | 34.1 (2.5)                           | 0.49|             |
| Other                   | 13.2 (2.9)                               | 22.0 (3.2)                           | 0.60|             |
| Education               |                                          |                                      |     |             |
| <High school (HS)       | 19.7 (1.6)                               | 33.3 (3.0)                           | 0.59|             |
| HS diploma or equivalent| 19.8 (1.5)                               | 36.8 (3.0)                           | 0.54|             |
| > HS                    | 18.0 (1.0)                               | 35.6 (2.5)                           | 0.51|             |
| Annual income           |                                          |                                      |     |             |
| $0 to $19,999           | 17.9 (0.9)                               | 28.6 (3.2)                           | 0.69|             |
| $20,000 to $49,999      | 22.3 (1.7)                               | 35.7 (1.5)                           | 0.62|             |
| ≥$50,000                | 17.1 (2.4)                               | 38.7 (2.0)                           | 0.44|             |
| Sexual orientation      |                                          |                                      |     |             |
| Homosexual or bisexual  | 17.6 (0.8)                               | 32.1 (5.9)                           | 0.67|             |
| Heterosexual or straight| 21.2 (1.3)                               | 34.6 (1.7)                           | 0.61|             |

CI = confidence interval, PR = prevalence ratio (unadjusted), SE = standard error, SPR = standardized prevalence ratio. Obese is defined as a body mass index ≥30.
Correlates of obesity differed for HIV-infected men (Table 3) and women (Table 4). In multivariable models, race/ethnicity, income, sexual orientation, and CD4 count were significant correlates of obesity in HIV-infected men receiving medical care; those with annual income under $50,000 but over $20,000, heterosexual men, and those with CD4 count greater than 200 cells/µL were more likely to be obese. Compared to black or African American men, Hispanic, or Latino HIV-infected men receiving medical care were less likely to be obese. Among women, only age remained a significant correlate of obesity after controlling for factors significant in bivariate models; HIV-infected women receiving medical care aged less than 40 years were more likely to be obese compared to those aged 60 years or more ($P = 0.04$). We found no statistically significant two-way interactions; therefore, they were not reported.

Among MMP participants, there were no differences in sociodemographic characteristics between individuals who had complete weight and height data (BMI directly calculated) and complete weight data only (inferred BMI). Compared to persons with complete weight and height data, those who were missing weight data (excluded from analysis) included significantly more women, more persons under the age of 40 years, and a higher proportion had detectable viral loads (eTable 4, http://links.lww.com/MD/A327). Among NHANES participants, few comparisons could be made due to small numbers of persons with complete weight data only and missing data among those who were excluded from the analysis (eTable 5, http://links.lww.com/MD/A327). In sensitivity analyses, the removal of persons with inferred BMI did not result in any substantial changes in findings; therefore, these results are not presented.

**DISCUSSION**

In this report, we present the first nationally representative estimates of obesity among HIV-infected adults receiving care in the United States. Similar to some previous studies, we found that 19% of HIV-infected men in medical care were obese and were approximately half as likely to be obese as men in the general U.S. population. However, our finding that 42% of HIV-infected women in medical care were obese is higher than previous estimates of obesity among HIV-infected women. Among MMP participants, there were no differences in sociodemographic characteristics between individuals who had complete weight and height data (BMI directly calculated) and complete weight data only (inferred BMI). Compared to persons with complete weight and height data, those who were missing weight data (excluded from analysis) included significantly more women, more persons under the age of 40 years, and a higher proportion had detectable viral loads (eTable 4, http://links.lww.com/MD/A327). Among NHANES participants, few comparisons could be made due to small numbers of persons with complete weight data only and missing data among those who were excluded from the analysis (eTable 5, http://links.lww.com/MD/A327). In sensitivity analyses, the removal of persons with inferred BMI did not result in any substantial changes in findings; therefore, these results are not presented.
that excess weight leads to improvements in HIV infection or outcomes overtime, it may simply be that more individuals are obese at time of infection or gain weight after initiating ART.22,53

For HIV-infected individuals in care and with well-controlled infection, a complementary strategy to address risk factors such as obesity is needed. Guidelines for the Management of Overweight and Obesity54 advise calculating BMI and measuring waist circumference at least annually for patients in the general population in addition to counseling for health goals, including weight loss, physical activity, and dietary modification. In HIV-infected populations, aerobic and resistance exercise have been shown to produce positive benefits for multiple outcomes, including body composition, functional capacity, muscular strength, and cholesterol.55 Although the effect of exercise and physical activity on immune function has not been determined, exercise has been shown to be safe and beneficial in HIV-infected adults. The guidelines for the general population could be followed until evidence accumulates to support guidelines specific to an HIV-infected population.

This study has several limitations. First, temporal associations cannot be established since MMP is cross-sectional. Also MMP had lower than optimal response rates, but data were weighted to adjust for nonresponse. Empirical research

### TABLE 3. Bivariate and Multivariable Associations of Sociodemographic Characteristics and Obesity in HIV-Infected Men in Care in the United States — Medical Monitoring Project (MMP) 2009

| Characteristics in Men | Bivariate | Multivariable |
|-----------------------|-----------|---------------|
| **Age at interview**  |           |               |
| 18–39 years           | 1.09 (0.78, 1.59) | – |
| 40–59 years           | 1.09 (0.78, 1.53) | – |
| ≥ 60 years            | Ref. | – |
| **Race/ethnicity**    |           |               |
| Black or African American | Ref. | – |
| White or Caucasian    | 0.86 (0.70, 1.06) | 0.84 (0.68, 1.05) |
| Hispanic or Latino/a  | 0.79 (0.65, 0.96) | 0.79 (0.65, 0.97) |
| Other                 | 0.62 (0.39, 0.98) | 0.53 (0.31, 0.89) |
| **Education**         |           |               |
| High school (HS)      | 1.10 (0.90, 1.34) | – |
| HS diploma or equivalent | 1.10 (0.92, 1.32) | – |
| > HS                  | Ref. | – |
| **Annual income**     |           |               |
| $0 to $19,999         | Ref. | – |
| $20,000 to $49,999    | 1.24 (1.04, 1.28) | 1.30 (1.07, 1.57) |
| $50,000+              | 0.95 (0.70, 1.29) | 0.95 (0.70, 1.27) |
| **Sexual orientation**|           |               |
| Homosexual or bisexual| Ref. | – |
| Heterosexual or straight | 1.21 (1.03, 1.41) | 1.21 (1.03, 1.42) |
| **Time since HIV diagnosis** | 0.65 | – |
| 0–5 years             | 1.03 (0.84, 1.26) | – |
| 5–10 years            | 1.10 (0.92, 1.31) | – |
| >10 years             | Ref. | – |
| **Geomeric mean CD4+ T-lymphocyte count, cells/µL** | 0.01 | 0.01 |
| 0–199                 | Ref. | Ref. |
| 200–349               | 1.57 (1.16, 2.12) | 1.51 (1.14, 2.01) |
| 350–499               | 1.73 (1.21, 2.48) | 1.74 (1.24, 2.44) |
| ≥500                  | 1.61 (1.13, 2.29) | 1.51 (1.03, 2.22) |
| **HIV disease stage** | 0.06 | 0.15 |
| Stage 1               | Ref. | Ref. |
| Stage 2               | 1.16 (0.97, 1.40) | 1.05 (0.85, 1.29) |
| Stage 3               | 1.35 (1.05, 1.74) | 1.37 (1.01, 1.86) |
| **Prescription of ART** | 0.53 | – |
| No                    | Ref. | – |
| Yes                   | 0.93 (0.74, 1.16) | – |
| **Viral suppression** | 0.87 | – |
| HIV viral load detectable | Ref. | – |
| HIV viral load undetectable | 1.01 (0.85, 1.21) | – |

aPR = adjusted prevalence ratio, ART = antiretroviral therapy, CI = confidence interval, PR = prevalence ratio.

Race/ethnicity categories are mutually exclusive.

Stage 3: AIDS diagnosis or lowest nadir CD4 < 200 cells/µL; stage 2: no AIDS diagnosis and lowest nadir CD4 of 200–499 cells/µL or CD4 percentage of 14% to < 29%; stage 1: no AIDS diagnosis and lowest nadir CD4 of ≥500 cells/µL or CD4 percentage ≥ 29%.27

Viral suppression: Undetectable indicates that the most recent viral load during the surveillance period was undetectable or ≤ 200 copies/mL. Detectable HIV viral load indicates that the most recent viral load during the surveillance period was undetectable or > 200 copies/mL or missing/unknown. Note: Bivariate associations with P-values < 0.15 from the Rao-Scott Chi-square statistic were included in multivariable models and are shown in bold. In multivariable models, data elements with P-values < 0.05 were considered significant and are shown in bold.
indicates that low response rates are not necessarily indicative of nonresponse bias, particularly when probabilistic samples are drawn from rigorously constructed sampling frames. 56

Although we were able to stratify our prevalence estimates by gender and standardize by one variable at a time, we were unable to standardize by multiple factors simultaneously, which might have aided interpretation of findings. Weight and height were abstracted from medical records across many different medical clinics in MMP and a standardized protocol for height and weight measurement was not used. Approximately 5% of MMP participants had no weight data and were excluded from the analysis. For those included in the analysis, nearly 21% were missing height data and BMI was inferred based on most likely BMI category according to recorded weight. Although some misclassification may have occurred, sensitivity analyses excluding persons with inferred BMI did not change the findings. Additionally, there were few differences in sociodemographic characteristics for participants who had complete weight and height data (BMI directly calculated), complete weight data only (inferred BMI), and those who were missing weight data (excluded from analysis). Physical activity and diet composition are associated with body composition and

### TABLE 4. Bivariate and Multivariable Associations of Sociodemographic Characteristics and Obesity in HIV-Infected Women in Care in the United States — Medical Monitoring Project (MMP) 2009

| Characteristics in Women | Bivariate | Multivariable |
|--------------------------|-----------|---------------|
|                          | Weighted % (95% CI) | P Value | aPR (95% CI) | P Value |
| Age at interview         |           | 0.02 | 0.04 |
| 18–39 years              | 1.50 (1.02, 2.21) |          | 1.47 (1.00, 2.18) |          |
| 40–59 years              | 1.25 (0.83, 1.90) |          | 1.28 (0.85, 1.94) |          |
| ≥60 years                | Ref.      |          | Ref.         |          |
| Race/ethnicity           |           | 0.07 | 0.09 |
| Black or African American| Ref.      |          | Ref.         |          |
| White or Caucasian       | 0.78 (0.60, 1.01) |          | 0.78 (0.60, 1.02) |          |
| Hispanic or Latino/a     | 0.79 (0.63, 1.00) |          | 0.78 (0.61, 0.99) |          |
| Other                    | 1.04 (0.72, 1.52) |          | 1.03 (0.72, 1.47) |          |
| Education                | 0.17      |          | –            |          |
| <High school (HS)        | 1.11 (0.96, 1.30) |          | –            |          |
| HS diploma or equivalent | 0.95 (0.81, 1.12) |          | –            |          |
| >HS                      | Ref.      |          | –            |          |
| Annual income            | 0.55      |          | –            |          |
| $0 to $19,999            | Ref.      |          | –            |          |
| $20,000 to $49,999       | 0.90 (0.74, 1.09) |          | –            |          |
| $50,000+                 | 1.05 (0.73, 1.52) |          | –            |          |
| Sexual orientation       | 0.23      |          | –            |          |
| Homosexual or bisexual   | Ref.      |          | –            |          |
| Heterosexual             | 1.26 (0.82, 1.94) |          | –            |          |
| Time since HIV diagnosis |           | 0.01 | 0.06 |
| >10 years                | Ref.      |          | Ref.         |          |
| 5–10 years               | 1.12 (0.95, 1.33) |          | 1.06 (0.89, 1.25) |          |
| 0–5 years                | 1.36 (1.14, 1.61) |          | 1.28 (1.06, 1.55) |          |
| Geometric mean CD4+ T-lymphocyte count, cells/μL | 0.24 |          | –            |          |
| 0–199                    | Ref.      |          | –            |          |
| 200–349                  | 1.25 (0.93, 1.68) |          | –            |          |
| 350–499                  | 1.45 (1.01, 2.09) |          | –            |          |
| ≥500                     | 1.31 (1.05, 1.65) |          | –            |          |
| HIV disease stage        |           | 0.07 | 0.15 |
| Stage 3                  | Ref.      |          | Ref.         |          |
| Stage 2                  | 1.24 (1.03, 1.48) |          | 1.19 (1.00, 1.43) |          |
| Stage 1                  | 1.12 (0.82, 1.52) |          | 1.06 (0.77, 1.45) |          |
| Prescription of ART      | 0.81      |          | –            |          |
| No                       | Ref.      |          | –            |          |
| Yes                      | 0.98 (0.80, 1.19) |          | –            |          |
| Viral suppression†       |           | 0.20 |          |
| HIV viral load detectable| Ref.      |          | –            |          |
| HIV viral load undetectable| 1.09 (0.95, 1.26) |          | –            |          |

Bivariate associations with P-values < 0.15 from the Rao-Scott Chi-square statistic were included in multivariable models and are shown in bold. In multivariable models, data elements with P-values < 0.05 from Wald multivariable Chi-square statistics were considered significant and are shown in bold. aPR = adjusted prevalence ratio, ART = antiretroviral therapy, CI = confidence interval, PR = prevalence ratio.

* Race/ethnicity categories are mutually exclusive. Stage 3: AIDS diagnosis or lowest nadir CD4 <200 cells/μL; stage 2: no AIDS diagnosis and lowest nadir CD4 of 200–499 cells/μL or CD4 percentage of 14% to <29%; stage 1: no AIDS diagnosis and lowest nadir CD4 of ≥500 cells/μL or CD4 percentage ≥29%.27

† Viral suppression: Undetectable indicates that the most recent viral load during the surveillance period was undetectable or ≤200 copies/mL. Detectable HIV viral load indicates that the most recent viral load during the surveillance period was undetectable or >200 copies/mL or missing/unknown.
weight, but are not available in MMP; therefore, we were not able to assess their association with obesity in these analyses.

In this analysis, we examined factors traditionally associated with obesity such as age, race/ethnicity, education, and income. We also considered sexual orientation, time since HIV diagnosis, HIV disease stage, current ART use, and current viral suppression. To our knowledge, this is the only nationally representative study examining obesity prevalence in an HIV-infected population receiving care.

In conclusion, we found that, HIV-infected men receiving medical care at HIV outpatient clinics were about half as likely to be obese but HIV-infected women receiving medical care at HIV outpatient clinics may be more likely to be obese, compared respectively to men and women in the general U.S. population. It is important to note that the prevalence of obesity in HIV-infected women was more than twice that of HIV-infected men. As ART becomes increasingly effective and more easily tolerated, achieving viral suppression is only the first step to ensuring long-term health for HIV-infected patients. Correlates of obesity differ for HIV-infected men and women; therefore, different strategies may be needed for obesity prevention and treatment to reduce morbidity and mortality from adverse long-term outcomes such as CVD.

ACKNOWLEDGMENTS
The authors thank all MMP and NHANES participants and staff members for their time and efforts; also thank Dr. Emma Frazier for MMP data analysis support.

REFERENCES
1. Torian L, Chen M, Hall I. HIV surveillance – United States, 1981–2008. MMWR. 2011;60:689–693.
2. Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the ‘HIV treatment as prevention’ experience in a Canadian setting. PLoS One. 2014;9:e87872.
3. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e51355.
4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–299.
5. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27:973–979.
6. Lewden C, Bouteloup V, De Wit S, et al. All-cause mortality in treated HIV-infected adults with CD4+ ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433–445.
7. Buchacz K, Baker RK, Palella FJ Jr et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18:65–75.
8. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.
9. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14:195–207.
10. Krentz HB, Klieger G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005;6:99–106.
11. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458–466.
12. Flegal KM, Graubard BI, Williamson DF, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007;298:2028–2037.
13. Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5:e10106.
14. Tate T, Willig AL, Willig JH, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17:1281–1289.
15. Freireg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–622.
16. Jones CY, Hogan JW, Snyder B, et al. Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV Epidemiology Research Study Cohort. Clin Infect Dis. 2003;37(Suppl 2):S69–S80.
17. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557–561.
18. Hendricks KM, Willis K, Houser R, et al. Obesity in HIV-infection: dietary correlates. J Am Coll Nutr. 2006;25:321–331.
19. Crum-Cianflone N, Tejidor R, Medina S, et al. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDs. 2008;22:925–930.
20. Keothe JR, Jenkins CA, Shepherd BE, et al. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis. 2011;53:952–960.
21. Kaplan RC, Landay AL, Hodis HN, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr. 2012;60:359–368.
22. Blashill AJ, Mayer KH, Crane HM, et al. Body mass index, immune status, and virological control in HIV-infected men who have sex with men. J Int Assoc Provid AIDS Care. 2013;12:319–324.
23. Lakey W, Yang LY, Yancey W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013;29:435–440.
24. Taylor BS, Liang Y, Garduño LS, et al. High risk of obesity and weight gain for HIV-infected uninsured minorities. J Acquir Immune Defic Syndr. 2014;65:e33–e40.
25. Frankel M, McNaghten A, Shapiro M, et al. A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. Open AIDS J. 2012;6:67–76.
26. Blair JM, Fagan JL, Frazier EL, et al. Behavioral and clinical characteristics of persons receiving medical care for HIV infection – Medical Monitoring Project, United States, 2009. MMWR Surveill Summ. 2014;63:1–28.
27. McNaghten AD, Wolfe M, Onorato I, et al. Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. PLoS One. 2007;2:e550–e1550.
28. Centers for Disease Control and Prevention. Medical Monitoring Project (MMP). In: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, Sexual Transmitted Diseases and Tuberculosis Prevention, Centers for Disease Control and Prevention. http://www.cdc.gov/hiv/statistics/systems/mmp/ [Accessed March 12, 2015].

29. Zipf G, Chiappa M, Porter KS, et al. National Health and Nutrition Examination Survey: plan and operations, 1999-2010. Vital Health Stat. 2013;1:37.

30. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES). In: National Center for Health Statistics, Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/nhanes.htm (Accessed March 12, 2015).

31. U.S. Department of Health and Human Services. Protection of Human Subjects, Title 45 code of Federal Regulations, Part 46. 2009. http://www.hhs.gov/ohrp/humansubjects/guidance/45cf46.html (Accessed August 19, 2014).

32. Centers for Disease Control and Prevention. Distinguishing public health research and public health non-research. In: Office of the Associate Director for Science, 2010. CDC-SA-2010-02. http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf (Accessed August 19, 2014).

33. Deputy NP, Boehmer U. Determinants of body weight among men of different sexual orientation. Prev Med. 2010;51:129–131.

34. U.S. Department of Health and Human Services. The Surgeon General’s call to action to prevent and decrease overweight and obesity. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001. Available from: U.S. GPO, Washington.

35. Drewnowski A, Specter SE. Poverty and obesity: the role of energy density and energy costs. Am J Clin Nutr. 2004;79:6–16.

36. Cohen AK, Rai M, Rehkopf DH, et al. Educational attainment and obesity: a systematic review. Obes Rev. 2013;14:989–1005.

37. Freedman DS, Khan LK, Serdula MK, et al. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA. 2002;288:1758–1761.

38. Selik RM, Mokotoff ED, Branson B, et al. Revised surveillance case definition for HIV infection – United States, 2014. MMWR Recomm Rep. 2014;63:1–10.

39. Boodram B, Plankey MW, Cox C, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women’s Interagency HIV Study. AIDS Patient Care STDS. 2009;23:1009–1016.

40. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143–3241.

41. U.S. Department of Commerce. Cumulative percent distribution of population by height and sex: 2007-2008. U.S. Census Bureau, Statistical Abstract of the United States: 2012. https://www.census.gov/compendia/ stabtab/2012/tabs/12st0209.pdf (Accessed August 19, 2014).

42. Rothman KJ, Greenland, S. Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.

43. Goldman DA, Breder JD. Are standardized mortality ratios valid for public health data analysis? Stat Med. 2000;19:1081–1088.

44. Rao JNK, Scott AJ. The analysis of categorical data from complex sample surveys: Chi-squared tests for goodness of fit and independence in two-way tables. J Am Stat Assoc. 1981;76:221–230.

45. Bieler GS, Brown GG, Williams RL, et al. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol. 2010;171:618–623.

46. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–497.

47. Fredriksen-Goldsen KI, Kim H-J, Barkan SE, et al. Health disparities among lesbian, gay, and bisexual older adults: results from a population-based study. Am J Public Health. 2013;103:1802–1809.

48. Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6:e22698.

49. Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013;13:964–975.

50. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among HIV-infected adults and the general adult population United States, 2009. Ann Intern Med. 2015;162:335–344.

51. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727–734.

52. Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J Acquir Immune Defic Syndr. 2000;23:81–88.

53. Crum-Cianflone N, Roediger M, Eberly L, et al. Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS. 2010;24:1069–1072.

54. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–S138.

55. Hand GA, Lyrer GW, Jaggers JR, et al. Impact of aerobic and resistance exercise on the health of HIV-infected persons. Am J Lifestyle Med. 2009;3:489–499.

56. Groves RM, Peytchiva E. The impact of nonresponse rates on nonresponse bias. Public Opin Q. 2008;72:167–189.

57. Hand GA, Jaggers JR, Lyrer GW, et al. Physical activity in cardiovascular disease prevention in patients with HIV/AIDS. Curr Cardiovasc Risk Rep. 2009;3:288–295.